Kazia Therapeutics Ltd (KZA)

1.22
+0.02(+1.67%)
  • Volume:
    204,404
  • Bid/Ask:
    1.205/1.30
  • Day's Range:
    1.19 - 1.25

KZA Overview

Prev. Close
1.2
Day's Range
1.19 - 1.25
Revenue
60K
Open
1.2
52 wk Range
0.364 - 1.88
EPS
-0.14
Volume
204,404
Market Cap
153.92M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
215,698
P/E Ratio
-
Beta
1.93
1-Year Change
236.4%
Shares Outstanding
126,166,264
Next Earnings Date
-
What is your sentiment on Kazia Therapeutics Ltd?
or
Market is currently closed. Voting is open during market hours.

Kazia Therapeutics Ltd News

Kazia Therapeutics Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy

Kazia Therapeutics Ltd Company Profile

Kazia Therapeutics Ltd Company Profile

Employees
12
Market
Australia

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.